BT-50 Main target antigen for atypical pANCA for use in diagnostic tests

Scientists at the University of Bonn, Germany, have identified the main target antigen for the atypical antineutrophil

cytoplasmic antibodies pANCA in autoimmune liver disorders and chronic inflammatory bowel diseases. BT-50 can be produced by recombinant means and used for the quantification of atypical pANCA in serum probes.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Innovative 3D printed scaffolds offer new hope for bone healing

Researchers at the Institute for Bioengineering of Catalonia have developed novel 3D printed PLA-CaP scaffolds that promote blood vessel formation, ensuring better healing and regeneration of bone tissue. Bone is…

The surprising role of gut infection in Alzheimer’s disease

ASU- and Banner Alzheimer’s Institute-led study implicates link between a common virus and the disease, which travels from the gut to the brain and may be a target for antiviral…

Molecular gardening: New enzymes discovered for protein modification pruning

How deubiquitinases USP53 and USP54 cleave long polyubiquitin chains and how the former is linked to liver disease in children. Deubiquitinases (DUBs) are enzymes used by cells to trim protein…